Suppr超能文献

一组长期血液透析患者的心房颤动与发病率和死亡率

Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.

作者信息

Genovesi Simonetta, Vincenti Antonio, Rossi Emanuela, Pogliani Daniela, Acquistapace Irene, Stella Andrea, Valsecchi Maria Grazia

机构信息

Dipartimento di Medicina Clinica e Prevenzione, Università degli Studi di Milano-Bicocca, Monza, Italy.

出版信息

Am J Kidney Dis. 2008 Feb;51(2):255-62. doi: 10.1053/j.ajkd.2007.10.034.

Abstract

BACKGROUND

Atrial fibrillation is associated with increased mortality and hospitalization in the general population. Data about mortality, morbidity, and hospitalization in hemodialysis patients with atrial fibrillation are limited.

SETTING & PARTICIPANTS: All patients (n = 476) in 5 dialysis centers in Lombardia, Italy, as of June 2003 were enrolled and followed up until June 2006 (median age, 69 years; median hemodialysis duration, 45.2 months; and median follow-up, 36 months). 127 patients had atrial fibrillation at enrollment.

PREDICTORS & OUTCOME: A Cox model was used to relate: (1) atrial fibrillation, age, hemodialysis therapy duration, and comorbid conditions to all-cause and cardiovascular mortality; (2) angiotensin-converting enzyme (ACE)-inhibitor treatment and comorbid conditions to new onset of atrial fibrillation; and (3) atrial fibrillation and comorbid conditions on hospitalization.

RESULTS

There were 167 deaths (39.5% from cardiovascular disease). In multivariable models, atrial fibrillation was independently associated with increased mortality (hazard ratio [HR], 1.65; 95% confidence interval [CI], 1.18 to 2.31). This was more notable for cardiovascular (HR, 2.15; 95% CI, 1.27 to 3.64) than noncardiovascular mortality (HR, 1.39; 95% CI, 0.89 to 2.15). New-onset atrial fibrillation occurred in 35 of 349 individuals (4.1 events/100 person-years); the risk of incident atrial fibrillation was lower in those using ACE-inhibitor therapy (HR, 0.29; 95% CI, 0.10 to 0.82) and higher in those with left ventricular hypertrophy (HR, 2.55; 95% CI, 1.04 to 6.26). There were 539 hospitalizations during 3 years, with 114 hospitalizations in 162 patients with atrial fibrillation and 155 hospitalizations in 314 patients without atrial fibrillation (HR, 1.54; 95% CI, 1.18 to 2.01). Rates of stroke did not significantly differ by atrial fibrillation status (P = 0.4).

LIMITATIONS

Because of the observational nature of this study, results for treatment need confirmation in future trials.

CONCLUSIONS

Atrial fibrillation is associated with greater total and cardiovascular mortality. Patients with atrial fibrillation were hospitalized more frequently than patients without atrial fibrillation. ACE inhibitors may decrease the risk of new-onset atrial fibrillation.

摘要

背景

在普通人群中,心房颤动与死亡率增加及住院率升高相关。关于心房颤动血液透析患者的死亡率、发病率和住院情况的数据有限。

设置与参与者

截至2003年6月,意大利伦巴第大区5个透析中心的所有患者(n = 476)均被纳入研究,并随访至2006年6月(中位年龄69岁;中位血液透析时间45.2个月;中位随访时间36个月)。127例患者在入组时患有心房颤动。

预测因素与结果

采用Cox模型来关联:(1)心房颤动、年龄、血液透析治疗时间和合并症与全因死亡率及心血管死亡率;(2)血管紧张素转换酶(ACE)抑制剂治疗和合并症与新发心房颤动;(3)心房颤动和合并症与住院情况。

结果

共发生167例死亡(39.5%死于心血管疾病)。在多变量模型中,心房颤动与死亡率增加独立相关(风险比[HR],1.65;95%置信区间[CI],1.18至2.31)。这在心血管死亡率方面(HR,2.15;95%CI,1.27至3.64)比非心血管死亡率方面(HR,1.39;95%CI,0.89至2.15)更为显著。349例个体中有35例发生新发心房颤动(4.1例事件/100人年);使用ACE抑制剂治疗的患者发生心房颤动的风险较低(HR,0.29;95%CI,0.10至0.82),而左心室肥厚患者的风险较高(HR,2.55;95%CI,1.04至6.26)。3年期间共发生539次住院,162例心房颤动患者中有114次住院,314例无心房颤动患者中有155次住院(HR,1.54;95%CI,1.18至2.01)。心房颤动状态对卒中发生率无显著差异(P = 0.4)。

局限性

由于本研究的观察性本质,治疗结果需要在未来试验中得到证实。

结论

心房颤动与更高的全因死亡率和心血管死亡率相关。心房颤动患者比无心房颤动患者住院更频繁。ACE抑制剂可能降低新发心房颤动的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验